[Development of anti tumor agents targeting angiogenesis]

Gan To Kagaku Ryoho. 1997 Jan;24(2):178-86.
[Article in Japanese]

Abstract

Aberrant angiogenesis is closely involved in invasion/metastasis as well as enlargement of tumor. One recent highlight is to develop anti angiogenic drugs by targeting tumor angiogenesis. Here we describe how tumor angiogenesis is regulated and also recent topics related to angiogenic drug in clinical trials.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Clinical Trials as Topic
  • Cyclohexanes
  • Drug Screening Assays, Antitumor
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Hydroxamic Acids*
  • Interferon-alpha / pharmacology
  • Interleukin-12 / pharmacology
  • Neoplasms / blood supply*
  • Neoplasms / pathology*
  • Neovascularization, Pathologic*
  • O-(Chloroacetylcarbamoyl)fumagillol
  • Phenylalanine / analogs & derivatives
  • Phenylalanine / pharmacology
  • Platelet Factor 4 / pharmacology
  • Polysaccharides, Bacterial / pharmacology
  • Sesquiterpenes / pharmacology
  • Thalidomide / pharmacology
  • Thiophenes / pharmacology
  • Triazines / pharmacology
  • Triazoles / pharmacology
  • Tumor Cells, Cultured / drug effects

Substances

  • Antineoplastic Agents
  • Cyclohexanes
  • Enzyme Inhibitors
  • Hydroxamic Acids
  • Interferon-alpha
  • Polysaccharides, Bacterial
  • Sesquiterpenes
  • Thiophenes
  • Triazines
  • Triazoles
  • streptococcal polysaccharide type III group B
  • Interleukin-12
  • Platelet Factor 4
  • Phenylalanine
  • Thalidomide
  • carboxyamido-triazole
  • batimastat
  • marimastat
  • irsogladine
  • O-(Chloroacetylcarbamoyl)fumagillol